



Faculty Disclosures Report

The joint IACH Meeting seeks to balance the important benefits of physician-industry relationships with the potential risk that the financial goals of the industry may conflict with the professional goals of joint IACH Meeting participants. In doing so, the joint IACH Meeting recognizes that it has a profound duty to its participants, the larger medical community and the public to ensure the integrity of all of its scientific, educational, and advocacy activities and materials.

Educational Content Development

The joint IACH Meeting requires all Program members and any others in a position to control the educational content to disclose any commercial financial interests prior to the development of the educational content. A process of resolution of conflict of interest is used for those members who do have financial interests related to the development of the content.

Presenters

The joint IACH Meeting considers financial relationships to create actual conflicts of interest when presenters have both a financial relationship with a commercial interest and the opportunity to affect the policy of the joint IACH Meeting of CME about the products or services of that commercial interest. The potential for Presenter to maintaining or increasing the value of the financial relationship with the commercial interest creates an incentive to influence the content of the CME – an incentive to insert commercial bias. All presenters of CME content should familiarize themselves with the policy of the joint IACH Meeting of CME based on the CME providers of the Meeting.

All joint IACH Meeting Faculty presenting CME are required to disclose the following prior to beginning their presentation:

- Any relevant financial relationships a CME presenter has had with manufacturers of commercial products or providers of commercial services within the past 12 months. The joint IACH Meeting defines "relevant" financial relationships as those with a commercial interest and the opportunity to affect the content of CME about the products or services of that commercial interest
- CME presenters who report they have no known relevant financial relationships to disclose will declare "No Financial Relationships"

Financial Disclosure Codes

Type of affiliation / financial interest	Code
Honorarium	H
Consultant	C
Other Financial or Material Support	F
Speakers' Bureau	S
Employee	E
Nothing to declare: <i>Written as said statement</i>	
Other: <i>Written as stated on submitted form</i>	

Disclosure Information

Financial interest disclosures from program members and others in a position for control content

The joint
COMyDAL, COLYM, MPNCo&D and 6th Annual Meeting of the International
Academy for Clinical Hematology (IACH)
October 5-7, 2023 | Paris, France & Online



Summary

Pau Abrisqueta, Spain

- H AbbVie, GenMab, Roche, Janssen, BMS, Astra Zeneca, BeiGene, Incyte
C AbbVie, GenMab, Roche, Janssen, Astra Zeneca, BeiGene, Incyte

Lionel Ades, France

- H BMS, Novartis, AbbVie
C BMS

Sairah Ahmed, USA

- F Research funding from Seattle Genetics, Merck, Zencor and Tessa Therapeutics
Other Membership on Tessa Therapeutics advisory committee

Jessica Altman, USA

- C AbbVie, Astellas Pharma, BioSight, Bluebird Bio, Curio, Gilead, Kura Oncology, Kymera, Rigel, Stemline Therapeutics, Syros
F Research funding (all to institution) from AbbVie, Agios, ALX Oncology, Amgen, Amphivena, Aprea AB, Aptose Biosciences, Astellas Pharma, BioSight, Boehringer Ingelheim, BMS, Celgene, Cycalcel, Fujifilm, Immunogen, Kartos Therapeutics, Kura Oncology, Loxo, Pfizer, Telios
Data monitoring committee for GlyoMimetics
S BioSight, Astellas Pharma, Daiichi Sankyo
Other HMP Global, MD Education, NCI, PeerView, EPICS/Aptitude Health

Leonor Arenillas, Spain

Nothing to declare

Farrukh Awan, USA

- C Genentech, Astra Zeneca, AbbVie, Janssen, Pharmacyclics, Gilead sciences, Kite Pharma, Celgene, Karyopharm, MEI Pharma, Verastem, Incyte, BeiGene, J&J, Dava Oncology, BMS, Merck, Cardinal Health, ADCT therapeutics, Epizyme, Caribou Biosciences, Collector Biosciences, Loxo Oncology, Adaptive Biotechnologies
F Research funding from Pharmacyclics

Tiziano Barbui, Italy

Nothing to declare

Frédéric Baron, Belgium

- H ExCelThera Inc.

Ali Bazarbachi, Lebanon

- H,S Roche, Takeda, Janssen, Novartis, Amgen, Pfizer

Didier Blaise, France

Nothing to declare

Eolia Brissot, France

- H,C,S Alexion, Amgen, Astellas, Gilead, Jazz Pharmaceuticals, Keocyt, MSD, Novartis, Sanofi, BMS, Pfizer

Lars Bullinger, Germany

- H,S AbbVie, Amgen, Astellas, BMS, Celgene, Daiichi Sankyo, Janssen, Jazz Pharmaceuticals, Novartis, Pfizer, Sanofi
C AbbVie, BMS, Celgene, Daiichi Sankyo, Gilead, Hexal, Janssen, Jazz Pharmaceuticals, Menarini, Novartis, Pfizer
F Research funding from Bayer, Jazz Pharmaceuticals

Antoine Capes, France

Nothing to declare

Sridhar Chaganti, UK

- H Kite-Gilead, Incyte, Novartis
F Kite-Gilead
S Kite-Gilead, Incyte

Julio Chavez, USA

- H Lilly US, Adaptive Biotechnologies
C Kite-Gilead, Novartis, AbbVie, Janssen

Sylvain Choquet, France

- C Atara, Pierre Fabre, Kite-Gilead, Novartis, Takeda, Astra Zeneca, Janssen, Viatrix, AbbVie

Fabio Ciceri, Italy

Nothing to declare

Thomas Cluzeau, France

- F Clinical research funding from Novartis, Alexion, Celgene/BMS, Amgen, Syros, Kartos, Arog, Takeda, Servier, Janssen
Advisory boards with Celgene, AbbVie, Jazz Pharmaceuticals, Novartis, Agios, Servier, BluePrint
Education: Novartis, Astellas, Celgene/BMS, Jazz Pharmaceuticals, Servier
S Pfizer, Celgene/BMS, Novartis, AbbVie

The joint
COMyDAL, COLYM, MPNCo&D and 6th Annual Meeting of the International
Academy for Clinical Hematology (IACH)
October 5-7, 2023 | Paris, France & Online



IACH

COMyDAL

COLYM

MPN
Co&D

Graham Collins, UK

H Takeda, Roche, Gilead, Incyte, MSD
S Takeda, Roche, Gilead, Incyte

Naval Daver, USA

Nothing to declare

Andrew Davies, UK

H,C Roche, BMS/Celgene, AbbVie, GenMab, Astra Zeneca,
Kite-Gilead
F Research support from MSD, Roche, Astra Zeneca

Laurence de Leval, Switzerland

C AbbVie, Bayer, Bio Ascend, Lunaphore, Novarits

Matteo Della Porta, Italy

Nothing to declare

María Díez Campelo, Spain

H BMS, Novartis,
C BMS, Novartis, Blue Print Medicines, GSK, Hemavant

Eva Domingo-Doménech, Spain

H Takeda

Rafael Duarte, Spain

H,C,S Alexion, Omeros corporation, Sobi

Anna Falanga, Italy

Nothing to declare

Pierre Fenaux, France

Nothing to declare

Robin Foà, Italy

Nothing to declare

Christopher Fox, UK

C AbbVie, Astra Zeneca, AtaraBio, BMS, GenMab, Kite-
Gilead, Incyte, Janssen, Lilly, Morphosys Ono, Roche,
Takeda
S AbbVie, Kite-Gilead, Janssen, Takeda, Roche
F Research funding from BeiGene

Michael Fradley, USA

C Astra Zeneca, AbbVie, J&J, Myovant/Pfizer
F Research grant from Medtronic

Andrea Gallamini, France

Nothing to declare

Alejandro Martín García-Sancho, Spain

H Roche, BMS/Celgene, Janssen, Kite-Gilead, Takeda
C Roche, BMS/Celgene, Kyowa Kirin, Clinigen, Kite-
Gilead, Incyte, Lilly, ADC Therapeutics America,
Miltenyi, Ideogen, AbbVie

Anna Godfrey, UK

Nothing to declare

Nicola Gökbüget, Germany

H, S Amgen, Celgene, Gilead, Novartis, Pfizer, Jazz
Pharmaceuticals, Incyte, Autolus, Clinigen, Servier,
Astra Zeneca
F Research support from Amgen, Pfizer, Novartis,
Shire/Servier, Jazz Pharmaceuticals, Incyte, Clinigen

Paola Guglielmelli, Italy

H,S Novartis, AbbVie, GSK, BMS

Mehdi Hamadani, USA

Nothing to declare

Claire Harrison, UK

Nothing to declare

Hans Hasselbalch, Denmark

Nothing to declare

Florian Heidel, Germany

H,C Novartis, CTI, BMS/Celgene, AOP Health, Janssen,
AbbVie, Amgen

Olivier Hermine, France

Nothing to declare

Alex Herrera, USA

C BMS, Genentech, Astra Zeneca, ADC Therapeutics,
Merck, Seattle Genetics, Karyopharm, Takeda,
Tubulis, Regeneron, GenMab, Pfizer, Caribou, Adicet
Bio, AbbVie

Michael Heuser, Germany

H Novartis, Pfizer, Jazz Pharmaceuticals, Janssen,
Certara, Sobi
C AbbVie, BMS, Glycostem, Servier, PinotBio, Amgen,
Pfizer, LaDelbert
F Research funding from AbbVie, Agios, Astellas,
BergenBio, BMS, Glycostem, Jazz Pharmaceuticals,
Karyopharm, Loxo Oncology, PinotBio

The joint
COMyDAL, COLYM, MPNCo&D and 6th Annual Meeting of the International
Academy for Clinical Hematology (IACH)
October 5-7, 2023 | Paris, France & Online



IACH

COMyDAL

COLYM

MPN
Co&D

Ronald Hoffman, USA

C Protagonist

Jean-Christophe Ianotto, France

Nothing to declare

Raphael Itzykson, France

H AbbVie, Astellas, Daiichi Sankyo, Gilead, Jazz
Pharmaceuticals, Novartis

F Research funding from AbbVie, Gilead, Jazz
Pharmaceuticals

Elias Jabbour, USA

Nothing to declare

Wojciech Jurczak, Poland

C AbbVie, Astra Zeneca, BeiGene, Lilly, Roche

Mohamed Kharfan-Dabaja, USA

Nothing to declare

Jean-Jacques Kiladjian, France

H Novartis, Incyte, AOP Health

C GSK, AbbVie

Rami Komrokji, USA

C Geron

S AbbVie, BMS, CTI BioPharma, Jazz Pharmaceuticals,
Pharma Essentia, Servier

Other Advisory Boards with Novartis, Taiho, Rigel

Elly Lugtenburg, Netherlands

H AbbVie, GenMab

F Research funding from Takeda

S Celgene, Lilly

Leonardo Magro, France

Nothing to declare

Florent Malard, France

H Sanofi, Mallinckrodt Therakos, Novartis

John Mascarenhas, USA

H Incyte, CTI, BMS, Celgene, Geron, AbbVie,
Karyopharm, Kartos, Pharma Esstentia, GSK,
Morphosys, Imago, Galecto, Pfizer, Sierra Oncology

Jonathan Mathias, UK

Nothing to declare

Donal McLornan, UK

H Jazz Pharmaceuticals, GSK, Novartis, BMS

S AbbVie, Novartis, BMS

Mary Frances McMullin, UK

Nothing to declare

Adam Mead, UK

H,C Novartis, Celgene/BMS, AbbVie, CTI, MD-Education,
Sierra Oncology, Medialis, Karyopharm, Sensyn,
Incyte, Galecto, Pfizer, Relay Therapeutics, GSK,
Alethiomics, Gilead

F Celgene/BMS, Novartis, Roche, Alethiomics, Galecto

Other AJM is founder and equity holder in Alethiomics Ltd, a
spin out company from the University of Oxford

Junia V. Melo, Australia

Nothing to declare

Ruben Mesa, USA

Nothing to declare

Klaus Metzeler, Germany

Nothing to declare

Mohamad Mohty, France

H Adaptive Biotechnologies, Amgen, Astellas, BMS, GSK,
Janssen, Jazz Pharmaceuticals, MaaT, Novartis, Pfizer,
Sanofi, Menarini Stemline, Takeda

C Janssen, Jazz Pharmaceuticals, MaaT, Sanofi,
Menarini Stemline

F Research funding from Janssen, Jazz Pharmaceuticals,
Sanofi

Advisory boards with BMS, GSK, Janssen, Jazz

Pharmaceuticals, Pfizer, Sanofi, Menarini Stemline

S Janssen, Jazz Pharmaceuticals, Sanofi

Alberto Mussetti, Spain

F Research funding from Kite-Gilead

Arnon Nagler, Israel

Nothing to declare

Olalekan Oluwole, USA

H Kite

C Kite, Gilead, ADC, TUR, Epizyme, Cargo Therapeutics

S ADC

David Patch, UK

H Bayer

The joint
COMyDAL, COLYM, MPNCo&D and 6th Annual Meeting of the International
Academy for Clinical Hematology (IACH)
October 5-7, 2023 | Paris, France & Online



IACH

COMyDAL

COLYM

MPN
Co&D

Naveen Pemmaraju, USA

Nothing to declare

Miguel Perales, USA

H Adicat, Allogene, Allovir, Caribou Biosciences,
Celgene, BMS, Equilium, Exevir, ImmPACT Bio, Incyte,
Karyopharm, Kite-Gilead, Merck, Miltenyi Biotec,
Morphosys, Nektar Therapeutics, Novartis, Omeros,
OrcaBio, Syncopation, VectivBio AG, Vor Biopharma
F Research funding (institutional) from Allogene, Incyte,
Kite-Gilead, Miltenyi Biotec, Nektar Therapeutics,
Novartis
Other DSMBs for Cidera Therapeutics, Medigene, Sellas Life
Sciences
Advisory Board for NexImmune
Ownership interests in NexImmune, Omeros, OrcaBio

Miguel Angel Piris, Spain

Nothing to declare

Lisa Pleyer, Austria

Nothing to declare

Isabelle Plo, France

F Financial research grant: Incyte – CALRmut antibodies

Bethan Psaila, UK

Nothing to declare

Deepti Radia, UK

H,C,S Blueprint Medicines, Cogent Biosciences

Raajit Rampal, USA

Nothing to declare

Andreas Reiter, Germany

H,S Novartis, GSK, Blueprint, BMS, AOP Health
C Novartis, GSK, Blueprint, BMS, AOP Health, Incyte

Marie Robin, France

Nothing to declare

Susan Robinson, UK

Nothing to declare

Gail Roboz, USA

C AbbVie, Amgen, Argenx, Astra Zeneca, Bluebird Bio,
Blueprint Medicines, BMS, Caribou Biosciences,
Celgene, Daiichi Sankyo, Ellipses Pharma, GSK,
Janssen, Jasper Pharmaceuticals, Jazz
Pharmaceuticals, Molecular Partners, Novartis, Pfizer,
Rigel, Roche, Syndax, Takeda (IRC Chair), Telix Pharma

Daniel Royston, UK

C Ground Truth Labs Ltd

Valeria Santini, Italy

Nothing to declare

Guillermo Sanz, Spain

H BMS, Roche
C AbbVie, BMS, ExCellera, Novartis, Takeda
F BeiGene
S BMS, Novartis, Takeda

Jaime Sanz Caballer, Spain

Nothing to declare

Bipin Savani, USA

Nothing to declare

Mayzar Shadman, USA

C AbbVie, Genentech, Astra Zeneca, Sound Biologics,
Pharmacyclics, BeiGene, BMS, Morphosys/Incyte, TG
Therapeutics, Innate Pharma, Kite Pharma, Adaptive
Biotechnologies, Epizymee, Eli Lilly, Adaptimmune,
Mustang Bio, Regeneron, Merck, Fate therapeutics,
MEI pharma, Atara Biotherapeutics
F Mustang Bio, Celgene, BMS, Pharmacyclics, Gilead,
Genentech, AbbVie, TG Therapeutics, BeiGene, Astra
Zeneca, Sunesis, Atara Biotherapeutics, GenMab,
Morphosys/Incyte, Vincerx

Roni Shouval, USA

Nothing to declare

Eric Solary, France

H Granite Bio, Blueprint Medicines, Novartis
F Research support from Amgen Foundation, Pepkon

Lena Specht, Denmark

H,C Kyowa Kirin, Takeda
F Research grants from Varian, ViewRay, Danish Cancer
Society

Marion Subklewe, Germany

F Research support from Amgen, BMS/Celgene, Gilead,
Janssen, Miltenyi, Morphosys, Novartis, Roche,
Seagen, Takeda
S Amgen, Astra Zeneca, BMS/Celgene, Gilead, GSK,
Miltenyi, Novartis, Pfizer, Roche, Takeda
Other Scientific advisory boards for AvenCell, CDR-life,
Ichnos Sciences, Incyte, Janssen, Miltenyi, Molecular
Partners, Novartis, Pfizer, Takeda

The joint
COMyDAL, COLYM, MPNCo&D and 6th Annual Meeting of the International
Academy for Clinical Hematology (IACH)
October 5-7, 2023 | Paris, France & Online



Anna Sureda, Spain

Nothing to declare

Hervé Tilly, France

H Roche, BMS, Incyte, ADC therapeutics

F Janssen, Gilead

Marek Trněný, Czech Republic

Nothing to declare

Carlos Vallejo, Spain

C,S Amgen, Pfizer, Gilead, MSD, Sanofi, Novartis, Jazz

Pharmaceuticals, Janssen, Alexion, Sobi, Roche,

Celgene

Arjan van de Loosdrecht, Netherlands

Nothing to declare

Andrew Wei, Australia

Nothing to declare

Ibrahim Yakoub-Agha, France

H BMS, Novartis, Kite, Janssen

Amer Zeidan, USA

Nothing to declare

Werner Zinkand, Germany

Nothing to declare